Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Kenya Pharmaceuticals And Healthcare Industry
SWOT — 6
Kenya Political SWOT — 7
Kenya Economic SWOT — 7
Kenya Business Environment
SWOT — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Middle East And North Africa
Pharmaceutical Business Environment Ratings — 9
Limits To
Potential Returns — 10
Risks To Realisation Of
Returns — 11
Kenya - Market
Summary — 12
Regulatory Regime — 13
Recent Regulatory Developments — 14
Counterfeit
Drugs — 15
Intellectual Property — 17
Pricing And Reimbursement Regime — 18
Kenya Medical Supply
Agency (KEMSA)’s Mandate — 19
Regional Regulatory
Developments — 20
Industry
Developments — 22
Epidemiology — 22
Table: Leading Causes Of Death In Kenya, 2002 — 25
Healthcare Provision — 25
Healthcare Sector
Financing — 27
Healthcare Reforms — 28
National Drug Policy — 30
Pharmaceutical
Sector — 30
Recent Pharmaceutical Industries
Activities — 31
Pharmaceutical
Distribution — 32
Supply Chain — 33
Traditional African Medicine — 34
Industry Forecast
Scenario — 37
Overall Market
Forecast — 37
Table: Kenya’s Drug Market
Expenditure, 2003-2013 — 37
Key Growth Factors –
Industry — 38
Table: Kenya’s Health Expenditure,
2003-2013 — 39
Key Growth Factors –
Macroeconomic — 40
Table: Kenya - Economic Activity,
2006-2013 — 42
Prescription Drug Market
Forecast — 43
Table: Kenya’s Prescription Drug
Market, 2003-2013 (US$mn unless otherwise indicated) — 44
OTC Drug Market Forecast — 45
Table: Kenya’s OTC
Market, 2003-2013 (US$mn unless otherwise stated) — 46
Patented Drug Market Forecast — 47
Table: Kenya’s
Patented Drug Market, 2003-2013 — 47
Generics Market
Forecast — 48
Table: Kenya’s Generic Drug Market,
2003-2013 — 49
Pharmaceutical Export/Import
Forecasts — 50
Table: Kenya’s Pharmaceutical Trade
Balance, 2003-2013 (US$mn) — 50
Other Healthcare Data
Forecasts — 51
Table: Kenya’s Other Health
Indicators, 2003-2013 — 51
Key Risks To BMI’s
Forecasts — 52
Competitive
Landscape — 53
Company Profiles — 54
Multinationals — 54
GlaxoSmithKline — 54
Pfizer — 56
Novartis — 57
Sanofi-Aventis — 58
Merck & Co — 59
Indigenous
Producers — 60
Dawa Limited — 60
Universal Corporation Limited — 62
Shelys
Pharmaceuticals — 64
Regal
Pharmaceuticals — 65
High Chem East
Africa — 66
Country Snapshot: Kenya Demographic
Data — 67
Section 1: Population — 67
Table: Demographic Indicators, 2005-2030 — 67
Table:
Rural/Urban Breakdown, 2005-2030 — 68
Section 2: Education
And Healthcare — 68
Table: Education,
2002-2005 — 68
Table: Vital Statistics,
2005-2030 — 68
Section 3: Labour Market And Spending
Power — 69
Table: Consumer Expenditure, 2000-2012
(US$) — 69
BMI Forecast Modelling — 70
How We Generate Our Pharmaceutical Industry Forecasts — 70
Pharmaceutical Business Environment Ratings
Methodology — 71
Ratings Overview — 71
Table: Pharmaceutical Business Environment Indicators — 72
Weighting — 73
Table: Weighting Of
Components — 73
Sources — 73
| 
View Cart
